Skip to Main Content

A panel of independent FDA advisers is meeting today to consider the merits of Spark Therapeutics’ (ONCE) Luxturna, a one-time gene therapy meant to treat a rare, inherited form of childhood blindness.

If the panel votes yes and the FDA follows its recommendation, Luxturna would become the first therapy meant to replace or repair a defective gene approved in the U.S. Spark hasn’t disclosed pricing, but analysts estimate Luxturna could cost $1 million or more per patient, a price that might force payers and insurers to rethink their coverage and reimbursement models.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Buenas tardes, quisiera que por favor me ayudaran tengo una sobrina de 38 anos , es sordomuda y tiene sindrome de Usher, retinitis pigmentosa, ha perdido la vision de los lados , este tratamiento pudiera ayudarle a ella, por favor me indican el costo es una persona de muy bajos recursos, se deprime mucho por esta condicion y no se como ayudarla. Gracias por ayudarnos Dios les de mucha sabiduria para que continuen en tan excelente labor.

Comments are closed.